FTC Approves Final Order Preserving Competition in U.S. Markets for Medical Devices Used in Cardiac and Vascular Catheterization
February 23, 2017
February 23, 2017
WASHINGTON, Feb. 23 -- The Federal Trade Commission issued the following news release:
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Abbott Laboratories' $25 billion acquisition of St. Jude Medical, Inc. would likely be anticompetitive.
First announced in December 2016, the FTC's complaint alleged that as proposed, the acquisition would likely harm competition in the U.S. markets for vascular closure . . .
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Abbott Laboratories' $25 billion acquisition of St. Jude Medical, Inc. would likely be anticompetitive.
First announced in December 2016, the FTC's complaint alleged that as proposed, the acquisition would likely harm competition in the U.S. markets for vascular closure . . .